Co beneldopa.JPG

Co beneldopa

CLINICAL USE

Treatment of Parkinsonism

DOSE IN NORMAL RENAL FUNCTION

150–800 mg daily in divided doses after meals (expressed as levodopa)

PHARMACOKINETICS

  • Molecular weight                           :Benserazide: 293.7 (as HCl), levodopa: 197.2
  • %Protein binding                           :Benserazide: 0, levodopa: 10–30
  • %Excreted unchanged in urine     : Benserazide: 0 (64 as metabs), levodopa: <1
  • Volume of distribution (L/kg)       :Benserazide: no data, levodopa: 0.36–1.6
  • half-life – normal/ESRD (hrs)      :Benserazide: 1.5/Increased, levodopa: 1.5/Increased by 25%

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysed. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAnaesthetics: risk of arrhythmias with volatile liquid anaesthetics such as halothaneAntidepressants: hypertensive crisis with MAOIs and linezolid (including moclobemide) – avoid for at least 2 weeks after stopping MAOIBupropion: increased risk of side effects of levodopaFerrous sulphate: reduces AUC of levodopa by 30–50%, clinically significant in some but not all patients

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Can be used to treat restless legs syndrome at a dose of 62.5–125 mgUrine may be red-tinged and turn dark on standing, due to metabolitesSerum uric acid and blood urea nitrogen levels are occasionally elevated